Asarfi Hospital's FY26 revenue target of ₹550 cr contradicts reported ₹173.5 cr
Management also reversed acquisition status from near-completion to early-stage, raising credibility concerns despite strong cancer-led growth.
What's new
- Cancer hospital expanding with ARPOB of ₹37,000 vs ₹23,000 for existing hospital.
- Revenue growth of ~40% since listing (no Q1 FY27 figures disclosed).
- PPP medical college proposed with ₹352 cr project cost, 60% government grant.
- No quarterly EBITDA or PAT disclosed; margin movement unattributed.
Themes from the call
Demand
Cancer-led growth with 95%+ oncology case coverage; screening camps in 10 districts building trust. Occupancy target ~75% for FY27-28 but bed utilization may understate oncology volume.
Margins
Radiation oncology margins benefit from fixed equipment costs; diagnostics (20% of revenue) also high-margin. No current margin bridge provided.
Capital allocation
70-bed acquisition underway (no valuation); PPP medical college requires balance funding from internal accruals, equity, and bank finance; multi-location expansion deferred pending model finalization.
Guidance watch
- FY26 revenue target ₹550 cr (inconsistent with reported ₹173.5 cr FY26 revenue).
- FY28 revenue target ₹400 cr (also inconsistent with ₹550 cr FY26 target).
- Bed occupancy target ~75% for FY27-28; cancer modality mix targets specified.
- Bone marrow transplant as soon as possible; organ transplant dependent on state policy.
Risk flags
- Revenue guidance contradictions raise questions about credibility and forecasting reliability.
- Acquisition status reversal suggests execution risk or incomplete due diligence.
- Government payor issues (Ayushman, GSS) described as manageable but recurring.
- No quantified EBITDA or PAT targets; margins opaque.
Key quotes
-
"Our FY26 revenue target is Rs 550 crores."
— Harinder Singh, CFO and Promoter -
"It is almost everything has been settled; only technical issues are being resolved. So, it is not aspirational, it is already..."
— Management, May 2026 call on acquisition
The brief
Asarfi Hospital's July concall presented a strong operational story — cancer ARPOB at ₹37,000, radiation margins supported by fixed cost structure, and a PPP medical college on the horizon. But the numbers don't add up. Management stated an FY26 revenue target of ₹550 crores, yet the FY26 books closed at ₹173.5 crores just two months ago. No reconciliation was offered. The same call saw the proposed 70-bed acquisition downgraded from 'almost settled' to 'process has begun' — a reversal that weakens confidence in management's timelines. The cancer-led strategy is logical for a regional hospital group serving underserved districts. Screening camps and employee doctor recruitment show execution traction. Diagnostics in-house at 20% of revenue support margins. Yet without quarterly financial disclosure or a credible bridge between stated targets and reported numbers, investors are left to guess. The FY28 target of ₹400 crores adds another layer of confusion — lower than the FY26 target but higher than current revenue. Management either misspoke or is recalibrating. Neither is reassuring. As long as the guidance remains irreconcilable, the operational progress is hard to underwrite.
Asarfi's cancer story is real, but the revenue contradictions make its guidance hard to trust. Credibility must come before scale.